EMA's committee for human medicines (CHMP) has approved additional manufacturing sites for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer.
One site, located in Reinbek, Germany, is operated by Allergopharma GmbH & Co. KG. The other in Stein, Switzerland, is operated by Novartis Pharma. The sites will perform finished product manufacturing steps at different stages of the process.
The two new sites are expected to support the continued supply of Comirnaty in the European Union.
This recommendation does not require a European Commission decision and the sites can become operational immediately.
The changes described will be included in the publicly available information on this vaccine.
Comirnaty: Paediatric investigation plan
Coronavirus disease (COVID-19)
COVID-19: latest updates
COVID-19 vaccines: authorised
COVID-19 vaccines: development, evaluation, approval and monitoring
Tel: +31 (0)88 781 8427
(C) 2021 Electronic News Publishing, source ENP Newswire